SCHEMBL1887054

SCHEMBL1887054

COc1ccc([C@H]2CC(=O)c3ccccc3O2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 12/20 1.00
▸ NPC1 O15118 2/20 1.00
▸ MAPT P10636 2/20 1.00
▸ RAB9A P51151 2/20 1.00
▸ CYP19A1 P11511 4/20 0.75
▸ CYP3A4 P08684 2/20 0.75
▸ AR P10275 2/20 0.73
▸ ABCB1 P08183 1/20 0.73
▸ ABCG2 Q9UNQ0 1/20 0.73
▸ ADORA3 P0DMS8 2/20 0.72
▸ KDM4E B2RXH2 1/20 0.72
▸ HSD17B10 Q99714 1/20 0.72
▸ MAPK1 P28482 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL127704 1.00 MAOB (1.00) MAOBNPC1MAPTRAB9ACYP19A1
SCHEMBL11252779 0.86 MAOB (0.76) MAOBNPC1MAPTRAB9ACYP19A1
SCHEMBL31562151 0.86 MAOB (0.76) MAOBNPC1MAPTRAB9ACYP19A1
Liquiritigenin Dimethyl Ether SCHEMBL3303937 0.86 CYP19A1 (1.00) MAOBNPC1MAPTRAB9ACYP19A1
SCHEMBL22680315 0.86 ABCB1 (0.87) MAOBNPC1MAPTRAB9ACYP19A1
Liquiritigenin Dimethyl Ether SCHEMBL13394438 0.86 CYP19A1 (1.00) MAOBNPC1MAPTRAB9ACYP19A1
SCHEMBL25437506 0.85 MAOB (0.74) MAOBNPC1MAPTRAB9ACYP19A1
Flavanone SCHEMBL19745 0.85 MAOB (1.00) MAOBNPC1MAPTRAB9ACYP19A1
Flavanone SCHEMBL12189591 0.85 MAOB (1.00) MAOBNPC1MAPTRAB9ACYP19A1
Flavanone SCHEMBL29843289 0.85 MAOB (1.00) MAOBNPC1MAPTRAB9ACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025091065-A1 FLAVONOID COMPOSITION GRETALS AUSTRALIA PTY LTD (AU) 2025-05-08 — — WO claimed
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2023-06-08 — — US claimed
EP-4146194-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS Gretals Australia Pty Ltd (AU) 2023-03-15 — — EP claimed
WO-2021222987-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2021-11-11 — — WO claimed
WO-2025091065-A1 FLAVONOID COMPOSITION GRETALS AUSTRALIA PTY LTD (AU) 2025-05-08 — — WO disclosed
CN-117761174-A Method for detecting metabolites in konjak and rhizosphere soil at different Pcc infection stages 昆明学院 2024-03-26 — — CN disclosed
EP-4307910-A1 FLAVORED FIBER BLENDS AND THEIR COMESTIBLE USE Firmenich SA (CH) 2024-01-24 — — EP disclosed
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2023-06-08 — — US disclosed
EP-4171266-A1 SWEETENING COMPOSITIONS AND USES THEREOF Firmenich SA (CH) 2023-05-03 — — EP disclosed
EP-4146194-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS Gretals Australia Pty Ltd (AU) 2023-03-15 — — EP disclosed
WO-2021259945-A1 SWEETENING COMPOSITIONS AND USES THEREOF FIRMENICH SA (CH) 2021-12-30 — — WO disclosed
WO-2021222987-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2021-11-11 — — WO disclosed
US-20090259055-A1 Catalytic enantioselective synthesis of flavanones and chromanones NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-10-15 — — US disclosed
US-20090259055-A1 Catalytic enantioselective synthesis of flavanones and chromanones NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-10-15 — — US disclosed
US-20080317880-A1 PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES THE SAMUEL ROBERTS NOBLE FOUNDATION 2008-12-25 — — US disclosed
WO-2008022265-A2 PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 2008-02-21 — — WO disclosed
EP-1625150-B9 TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE PENTAPHARM AG (CH) 2007-06-13 — — EP disclosed
EP-1625150-B1 TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE PENTAPHARM AG (CH) 2007-01-03 — — EP disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 — — WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259055-A1 Catalytic enantioselective synthesis of flavanones and chromanones RNGTT, CDK20, TBXAS1 MAOB 458/4885NPC1 4587/4885MAPT 4627/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP MAOB 652/4885NPC1 3898/4885MAPT 4313/4885
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS MMP1, COL1A1, SERPINB1 MAOB 2184/4885NPC1 1063/4885MAPT 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback